Literature DB >> 3436096

Heterogeneity of biochemical, clinical and immunological parameters in severe combined immunodeficiency due to adenosine deaminase deficiency.

G Morgan1, R J Levinsky, K Hugh-Jones, L D Fairbanks, G S Morris, H A Simmonds.   

Abstract

There was considerable heterogeneity of the biochemical, clinical and immunological findings in 12 patients and two fetuses from 16 kindreds affected by severe combined immunodeficiency (SCID) due to a complete deficiency of the enzyme adenosine deaminase (ADA). Despite this heterogeneity a consistent pattern was observed, in which levels of abnormal purine metabolites paralleled the severity of the immunodeficiency. A high level of urinary deoxyadenosine was a universal finding for homozygous ADA deficiency. ATP depletion, in association with raised deoxy-ATP (dATP) levels, was found in the erythrocytes of nine infants with profound cellular and humoral immunodeficiency. There was no erythrocyte ATP depletion in two patients with some residual immunity, who presented later, but adenosine accumulated in their plasma and urine. This finding, together with the presence of some T and normal B-lymphocytes in less severely affected patients, suggests that adenosine is relatively non-toxic. The other results are consistent with the hypothesis that the sequence of deoxyadenosine accumulation, dATP formation and ATP depletion represents the major mechanism of toxicity to the immune system. Low numbers of T lymphocytes and dATP accumulation were also found in the blood of affected fetuses at 18 weeks gestation. Since extreme instability of erythrocyte ADA was demonstrated in some heterozygotes, and heterozygote ADA levels were detected in one infant with SCID, simultaneous immunological and biochemical analysis of fetal blood are important for precise antenatal diagnosis.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3436096      PMCID: PMC1542189     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  17 in total

1.  In vitro platelet abnormality in adenosine deaminase deficiency and severe combined immunodeficiency.

Authors:  C H Lee; S P Evans; M C Rozenberg; A S Bagnara; J B Ziegler; M B Van der Weyden
Journal:  Blood       Date:  1979-03       Impact factor: 22.113

2.  Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity.

Authors:  E R Giblett; J E Anderson; F Cohen; B Pollara; H J Meuwissen
Journal:  Lancet       Date:  1972-11-18       Impact factor: 79.321

3.  Rapid prenatal diagnosis of adenosine deaminase deficiency and other purine disorders using foetal blood.

Authors:  H A Simmonds; L D Fairbanks; D R Webster; C H Rodeck; D C Linch; R J Levinsky
Journal:  Biosci Rep       Date:  1983-01       Impact factor: 3.840

4.  The chondro-osseous dysplasia of adenosine deaminase deficiency with severe combined immunodeficiency.

Authors:  S D Cederbaum; I Kaitila; D L Rimoin; E R Stiehm
Journal:  J Pediatr       Date:  1976-11       Impact factor: 4.406

5.  Reciprocal relationship between erythrocyte ATP and deoxy-ATP levels in inherited ADA deficiency.

Authors:  H A Simmonds; R J Levinsky; D Perrett; D R Webster
Journal:  Biochem Pharmacol       Date:  1982-03-15       Impact factor: 5.858

6.  Formation and degradation of deoxyadenosine nucleotides in inherited adenosine deaminase deficiency.

Authors:  H A Simmonds; D R Webster; D Perrett; S Reiter; R J Levinsky
Journal:  Biosci Rep       Date:  1982-05       Impact factor: 3.840

7.  Abnormal platelet aggregation in severe combined immunodeficiency disease with adenosine deaminase deficiency.

Authors:  A L Schwartz; S H Polmar; R C Stern; D H Cowan
Journal:  Br J Haematol       Date:  1978-06       Impact factor: 6.998

8.  Severe combined immunodeficiency and adenosine deaminase deficiency: failure of enzyme replacement therapy.

Authors:  J B Ziegler; C H Lee; M B Van der Weyden; A S Bagnara; J Beveridge
Journal:  Arch Dis Child       Date:  1980-06       Impact factor: 3.791

9.  Purine metabolism in adenosine deaminase deficiency.

Authors:  H A Simmonds; A Sahota; C F Potter; D Perrett; K Hugh-Jones; J G Watson
Journal:  Ciba Found Symp       Date:  1978

10.  Decreased S-adenosylhomocysteine hydrolase in inborn errors of purine metabolism.

Authors:  J E Kaminska; I H Fox
Journal:  J Lab Clin Med       Date:  1980-07
View more
  13 in total

Review 1.  Severe combined immunodeficiency--molecular pathogenesis and diagnosis.

Authors:  H B Gaspar; K C Gilmour; A M Jones
Journal:  Arch Dis Child       Date:  2001-02       Impact factor: 3.791

Review 2.  Severe combined immunodeficiencies (SCID).

Authors:  A Fischer
Journal:  Clin Exp Immunol       Date:  2000-11       Impact factor: 4.330

3.  The number of plaque-forming cells and its "normal range".

Authors:  M Jílek
Journal:  Folia Microbiol (Praha)       Date:  1989       Impact factor: 2.099

Review 4.  Prenatal diagnosis and carrier detection in primary immunodeficiency disorders.

Authors:  Y L Lau; R J Levinsky
Journal:  Arch Dis Child       Date:  1988-07       Impact factor: 3.791

5.  Adenosine deaminase deficiency with altered biochemical parameters in two sisters with late-onset immunodeficiency.

Authors:  L D Fairbanks; C L Shovlin; A D Webster; J M Hughes; H A Simmonds
Journal:  J Inherit Metab Dis       Date:  1994       Impact factor: 4.982

6.  Correct splicing despite mutation of the invariant first nucleotide of a 5' splice site: a possible basis for disparate clinical phenotypes in siblings with adenosine deaminase deficiency.

Authors:  F X Arredondo-Vega; I Santisteban; S Kelly; C M Schlossman; D T Umetsu; M S Hershfield
Journal:  Am J Hum Genet       Date:  1994-05       Impact factor: 11.025

7.  Adenosine-deaminase-associated immunodeficiency. I. Differential sensitivities of lymphocyte subpopulations exposed to 2-deoxycoformycin in vivo.

Authors:  O Bagasra; A Howeedy; R J Pomerantz
Journal:  Clin Exp Immunol       Date:  1992-06       Impact factor: 4.330

8.  Gene therapy/bone marrow transplantation in ADA-deficient mice: roles of enzyme-replacement therapy and cytoreduction.

Authors:  Denise A Carbonaro; Xiangyang Jin; Xingchao Wang; Xiao-Jin Yu; Nora Rozengurt; Michael L Kaufman; Xiaoyan Wang; David Gjertson; Yang Zhou; Michael R Blackburn; Donald B Kohn
Journal:  Blood       Date:  2012-07-25       Impact factor: 22.113

9.  Insulin-dependent diabetes mellitus and severe atopic dermatitis in a child with adenosine deaminase deficiency.

Authors:  L D Notarangelo; G Stoppoloni; R Toraldo; E Mazzolari; A Coletta; P Airò; C Bordignon; A G Ugazio
Journal:  Eur J Pediatr       Date:  1992-11       Impact factor: 3.183

10.  Successful bone marrow transplantation and treatment of BCG infection in two patients with severe combined immunodeficiency.

Authors:  R S Heyderman; G Morgan; R J Levinsky; S Strobel
Journal:  Eur J Pediatr       Date:  1991-05       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.